Sigma-Aldrich) into the common bile duct
GLP-1 agonists were originally approved to treat Type 2 Diabetes (T2D) but their most recent incarnations, which consist of both next generation GLP-1s and combinations (Ozempic, Mounjaro, Wegovy, Zepbound), have moved beyond the realm of T2D into the treatment of obesity
Subcutaneous administration in normal and metabolically dysregulated mice significantly inhibits NNMT activity in metabolically active tissues (adipose, liver, muscle), increases systemic NAD+ levels, enhances mitochondrial function, and improves energy metabolism
Industry analysts project a potential launch in 2028, though timelines could shift depending on regulatory review
Animals were administered with the drugs in a different room from that they were housing and from where the behavioral experiments were performed